NCT02672436

ENERGI-F703 for Diabetic Foot Ulcers Phase II Study

A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F703 in Subjects With Diabetic Foot Ulcers

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 141 (actual)
• Sponsor: Energenesis Biomedical Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the efficacy and safety of ENERGI-F703 in subject with diabetic foot ulcers.

Conditions

• Diabetic Foot
• Foot Ulcer
• Diabetes Mellitus
• Wounds

Interventions

Type	Name	Description
DRUG	ENERGI-F703	Standard of care and ENERGI-F703 are applied for treatment of diabetic foot ulcers.
DRUG	ENERGI-F703 matched vehicle	Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.

Timeline

• Start date: 2017-03-15
• Primary completion: 2019-10-03
• Completion: 2019-12-26
• First posted: 2016-02-03
• Last updated: 2020-11-24

Locations

1 site across 1 country: Taiwan

Regulatory

• FDA-regulated drug study